Mayo Clinic, WuXi AppTec diagnostics joint venture to open first R&D center in the U.S.

test tubes
Previously, the WuXi Diagnostics joint venture aimed to co-develop and deliver clinical diagnostic services in China. (Pixabay)

WuXi Diagnostics, a joint venture launched last year by WuXi AppTec and Mayo Clinic, is planning to open its first U.S.-based R&D center just down the street from its benefactor in Rochester, Minnesota.

The facility, to be based in the new life sciences center One Discovery Square, is expected to open before the end of this year.

It will serve as a center of WuXi Diagnostics’ development of clinical diagnostic tests and will work in collaboration with Mayo’s department of laboratory medicine and pathology as well as its Advanced Diagnostics Laboratory.


CIOs’ Perspectives: Driving Clinical Trial Innovation with a Unified Platform

IT is being challenged with either trying to fix and maintain an already complex system of solution integrations, or exploring driving business impact by unifying its systems under one platform. Attend and learn about the IT benefits to shifting resources away from disparate systems and moving towards a unified platform.

"Our new facility will directly contribute to our further cooperation with Mayo Clinic," WuXi Diagnostics CEO Jason Liu said in a statement. "It will leverage WuXi Diagnostics' research and development capability and Mayo Clinic's advanced clinical practice to accelerate esoteric diagnostic product development and to transform discoveries into diagnostic tests that will benefit all."

RELATED: WuXi opens CAR-T biomanufacturing facility in Philadelphia

Previously, the joint venture aimed to co-develop and deliver clinical diagnostic services in China.

"This facility allows us to further leverage our existing knowledge and expertise in the esoteric diagnostics in a wide range of areas–cancer, hematology, neurology, gastroenterology, genetics, to name just a few–to provide patients worldwide with laboratory testing that addresses their specific health care needs," said William Morice II, president of Mayo Clinic Laboratories and chair of laboratory medicine and pathology at Mayo Clinic.

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

The FDA approved its first rapid in vitro diagnostic for confirming Ebola virus infections with potential results in about a half-hour.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.